KR20010097870A - Beverage composition for improving degenerative arthritis and method thereof - Google Patents
Beverage composition for improving degenerative arthritis and method thereof Download PDFInfo
- Publication number
- KR20010097870A KR20010097870A KR1020000022288A KR20000022288A KR20010097870A KR 20010097870 A KR20010097870 A KR 20010097870A KR 1020000022288 A KR1020000022288 A KR 1020000022288A KR 20000022288 A KR20000022288 A KR 20000022288A KR 20010097870 A KR20010097870 A KR 20010097870A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- beverage composition
- degenerative arthritis
- glucosamine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 45
- 235000013361 beverage Nutrition 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims description 6
- 239000000284 extract Substances 0.000 claims abstract description 69
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 24
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960002442 glucosamine Drugs 0.000 claims abstract description 24
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930091371 Fructose Natural products 0.000 claims abstract description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 10
- 239000005715 Fructose Substances 0.000 claims abstract description 10
- 235000013736 caramel Nutrition 0.000 claims abstract description 10
- 235000012907 honey Nutrition 0.000 claims abstract description 10
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 8
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 7
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 7
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 229940069774 quince extract Drugs 0.000 claims abstract description 7
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 6
- 210000003056 antler Anatomy 0.000 claims abstract description 5
- 235000021374 legumes Nutrition 0.000 claims abstract description 3
- 229920001661 Chitosan Polymers 0.000 claims description 16
- 229920001542 oligosaccharide Polymers 0.000 claims description 12
- 150000002482 oligosaccharides Chemical class 0.000 claims description 12
- 241000411851 herbal medicine Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 6
- 239000013505 freshwater Substances 0.000 claims description 4
- 241000282994 Cervidae Species 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 208000004296 neuralgia Diseases 0.000 abstract description 9
- 230000032683 aging Effects 0.000 abstract description 8
- 206010003246 arthritis Diseases 0.000 abstract description 8
- 210000000845 cartilage Anatomy 0.000 abstract description 7
- 210000000988 bone and bone Anatomy 0.000 abstract description 5
- 230000005786 degenerative changes Effects 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 40
- 229940016409 methylsulfonylmethane Drugs 0.000 description 18
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 18
- 208000006820 Arthralgia Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 230000006872 improvement Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 230000007815 allergy Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 6
- 208000007613 Shoulder Pain Diseases 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 240000001439 Opuntia Species 0.000 description 4
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 4
- 244000251905 Pseudocydonia sinensis Species 0.000 description 4
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 4
- 235000013527 bean curd Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940045110 chitosan Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- DPHQKFPANOYYOP-BCOUGSAOSA-N CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O DPHQKFPANOYYOP-BCOUGSAOSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001147791 Clostridium paraputrificum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000186568 Hathewaya limosa Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 241000193157 Paraclostridium bifermentans Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- -1 steroids saponins Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/606—Fructose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 40대 이후에 점진적으로 진행되어 50대에 이르러 호발하는 신경통, 특히, 관절을 구성하는 연골과 그 주위의 뼈에 퇴행성 변화가 나타나서 생기는 관절염으로 오랫동안 방치하면 관절의 변형까지 초래하는 퇴행성관절염 등, 신체적 노화에 따른 질병을 개선하는 음료 조성물 및 그 제조방법에 관한 것이다. 본 발명의 음료 조성물은 1.45 내지 2.0 중량의 녹용 추출액, 10 내지 15중량의 가시오가피 추출액, 5 내지 12중량의 복분자 추출액, 10 내지 15중량의 맥문동 추출액, 5 내지 12중량의 구기자 추출액, 5 내지 12중량의 백출 추출액, 10 내지 15중량의 법제두충 추출액, 10 내지 15중량의 당귀 추출액, 10 내지 15중량의 모과 추출액, 10 내지 16중량의 갈근 추출액, 0.6 내지 1.2중량의 글루코사민, 0.6 내지 1.2중량의 MSM, 0.1 내지 0.5 중량의 키토산올리고당, 2.5 내지 4.0중량의 꿀, 2.5 내지 4.0중량의 액상과당, 및 0.2내지 0.4중량의 카라멜을 포함한다.The present invention is gradually progressed after the 40s, the neuralgia, which occurs in the 50s, especially degenerative arthritis that leads to deformation of the joint when left for a long time with arthritis caused by degenerative changes in the cartilage constituting the joint and surrounding bones The present invention relates to a beverage composition and a method for producing the same, which improve diseases caused by physical aging. The beverage composition of the present invention is 1.45 to 2.0 weight of antler extract, 10 to 15 weight of thorny opi extract, 5 to 12 weight of Bokbunja extract, 10 to 15 weight of ginmundong extract, 5 to 12 weight of wolfberry extract, 5 to 12 weight White extract, 10-15 weight legume extract, 10-15 weight Angelica extract, 10-15 weight quince extract, 10-16 weight root extract, 0.6-1.2 weight glucosamine, 0.6-1.2 weight MSM , 0.1-0.5 weight chitosan oligosaccharide, 2.5-4.0 weight honey, 2.5-4.0 weight liquid fructose, and 0.2-0.4 weight caramel.
Description
본 발명은 유효성분으로서 글루코사민, 메틸 술포닐 메탄(MSM) 및 키토산올리고당과 한방의 천연약재를 함유하여, 신경통, 특히, 퇴행성관절염 등의 노화에 따른 질병을 개선하는 음료 조성물 및 이의 제조 방법에 관한 것이다.The present invention contains a glucosamine, methyl sulfonyl methane (MSM) and chitosan oligosaccharides and herbal natural medicines as an active ingredient, and relates to a beverage composition and a method for preparing the same for improving diseases caused by aging such as neuralgia, especially degenerative arthritis. will be.
현대 사회가 점점 고도화되고 복잡해짐에 따라 사회생활 등에 따른 스트레스, 공업화에 따른 대기 공해의 증가, 환경오염에 따른 환경호르몬의 발현등 심각한 사회문제로 대두되어 지고 있고, 점차 나이가 들어감에 따른 여러 가지 질병의 발생은 신체적 노화의 자연적인 현상으로 받아들이고 있는 것이 오늘날의 현실이다. 특히, 40대 이후 점진적으로 진행하여 50대부터 발현하는 성인병, 생활 습관성병, 퇴행성관절염, 관절통, 오십견은 그 대표적인 예라 할 수 있다. 퇴행성관절질환이라고 불리는 일차적 관절염은 50대 이상의 대다수를 괴롭히는 질환으로 치료 방법이나 예방 방법이 한두 가지가 아니지만 확실한 예방과 호전을 기대할 수 있는 경우는 그리 많지 않다. 이에, 신경통, 특히, 퇴행성관절염의 예방 효과를 나타내면서, 효과적으로 질환을 호전시킬 수 있는 음료 조성물이 여전히 요구되고 있다.As modern society becomes more advanced and complicated, it is becoming a serious social problem such as stress due to social life, increase of air pollution due to industrialization, and expression of environmental hormone due to environmental pollution. It is a reality today that the occurrence of disease is taken as a natural phenomenon of physical aging. In particular, adult disease, lifestyle disease, degenerative arthritis, arthralgia, and fifty shoulders, which gradually progress after the forties, are expressed in the fifties. Primary arthritis, called degenerative joint disease, is a disease that afflicts the majority of people over 50 years of age. However, there are not one or two treatments or preventive measures, but there are not many cases where certain prevention and improvement can be expected. Accordingly, there is still a need for a beverage composition that can effectively improve the disease while exhibiting a prophylactic effect of neuralgia, especially degenerative arthritis.
따라서, 본 발명의 목적은 신경통, 특히, 퇴행성관절염의 개선에 아주 유용한 효능이 있는 음료 조성물을 제공하는데 있다.Accordingly, it is an object of the present invention to provide a beverage composition which is very useful for improving neuralgia, especially degenerative arthritis.
본 발명은 신경통, 특히, 퇴행성관절염의 개선에 아주 유용한 효능이 있는 음료 조성물을 제공한다.The present invention provides a beverage composition that is very useful for improving neuralgia, especially degenerative arthritis.
본 발명은 한방의 천연약재에 신경통, 특히, 퇴행성관절염에 효과가 있는 유효 성분을 혼합함으로써, 퇴행성관절염의 기능강화에 의한 퇴행성관절염의 예방효과는 물론, 효과적으로 질환을 호전시킬 수 있는 음료 조성물을 제공하고 있다.The present invention provides a beverage composition that can effectively improve the disease as well as prevent the effect of degenerative arthritis by strengthening the function of the degenerative arthritis by mixing the herbal medicine with an active ingredient effective for neuralgia, in particular, degenerative arthritis. Doing.
상기 목적을 달성하기 위해서, 본 발명은 유효성분으로서 글루코사민, 메틸술포닐 메탄(MSM) 및 키토산올리고당과 한방의 천연약재를 함유하여, 신경통, 특히, 퇴행성관절염등의 노화에 따른 질병을 개선하는 음료 조성물을 제공하고 있다.In order to achieve the above object, the present invention contains glucosamine, methylsulfonyl methane (MSM) and chitosan oligosaccharides and herbal natural herbs as an active ingredient, beverages to improve the disease caused by aging, such as neuralgia, especially degenerative arthritis A composition is provided.
본 발명은 한방 약재와 글루코사민, MSM 및 키토산올리고당을 함유하는 음료 조성물에 관한 것이다. 본 발명의 퇴행성관절염 개선 음료 조성물은 한방 약재와 0.6 내지 1.2중량의 글루코사민, 0.6 내지 1.2중량의 MSM, 및 0.1 내지 0.5 중량의 키토산올리고당을 함유한다.The present invention relates to a herbal composition and a beverage composition containing glucosamine, MSM and chitosan oligosaccharides. The degenerative arthritis improving beverage composition of the present invention contains the herbal medicine and 0.6 to 1.2 weight of glucosamine, 0.6 to 1.2 weight of MSM, and 0.1 to 0.5 weight of chitosan oligosaccharide.
본 발명의 음료 조성물은 바람직하게 1.45 내지 2.0 중량의 녹용 추출액, 10 내지 15중량의 가시오가피 추출액, 5 내지 12중량의 복분자 추출액, 10 내지 15중량의 맥문동 추출액, 5 내지 12중량의 구기자 추출액, 5 내지 12중량의 백출 추출액, 10 내지 15중량의 법제두충 추출액, 10 내지 15중량의 당귀 추출액, 10 내지15중량의 모과 추출액, 10 내지 16중량의 갈근 추출액, 0.6 내지 1.2중량의 글루코사민, 0.6 내지 1.2중량의 MSM, 0.1 내지 0.5 중량의 키토산올리고당, 2.5 내지 4.0중량의 꿀, 2.5 내지 4.0중량의 액상과당, 및 0.2내지 0.4중량의 카라멜을 포함한다.The beverage composition of the present invention is preferably 1.45 to 2.0 weight of antler extract, 10 to 15 weight of thorny ovine extract, 5 to 12 weight of Bokbunja extract, 10 to 15 weight of ginmundong extract, 5 to 12 weight of wolfberry extract, 5 to 12 weight extract, 10-15 weight legume extract, 10-15 weight Angelica extract, 10-15 weight quince extract, 10-16 weight root extract, 0.6-1.2 weight glucosamine, 0.6-1.2 weight MSM, 0.1-0.5 weight chitosan oligosaccharide, 2.5-4.0 weight honey, 2.5-4.0 weight liquid fructose, and 0.2-0.4 weight caramel.
한편, 상기한 본 발명의 퇴행성관절염 개선 음료의 조성에 있어서 각 구성성분의 첨가량이 전술한 첨가량 보다 적은 경우에는 바람직한 퇴행성관절염 개선 효과가 나타나지 않았으며 전술한 첨가량 보다 많은 경우에는 첨가량에 비례하여 퇴행성관절염 개선 효과가 크게 상승하지 않으면 제조 원가의 상승을 초래하여 경제성이 떨어진다.On the other hand, in the composition of the degenerative arthritis improving beverage of the present invention, when the amount of each component is less than the above-mentioned amount, the degenerative arthritis improvement effect is not exhibited. If the improvement does not increase significantly, manufacturing costs will rise and economic efficiency will decline.
상기한 본 발명의 목적을 달성하기 위한 퇴행성관절염 개선 천연 음료 조성물의 제조 방법은 천연 한약재를 엄격히 선별하여 청수를 가한 후에 90 내지 97℃에서 6 내지 10시간 동안 추출하여 여과한 후 추출원액을 얻는 단계, 상기 추출원액에 글루코사민, MSM, 키토산올리고당을 80 내지 90℃에서 혼합한 후 꿀과 과당, 및 카라멜을 혼합하는 단계, 상기 혼합액을 90 내지 100℃에서 15 내지 30초 고온 살균처리하여 퇴행성관절염 개선 천연 음료를 수득하는 단계를 포함한다.Method of producing a degenerative arthritis improved natural beverage composition for achieving the above object of the present invention is to strictly extract the natural herbal medicine and then added fresh water, and then extracted and filtered for 6 to 10 hours at 90 to 97 ℃ to obtain an extract stock solution , Mixing glucosamine, MSM, and chitosan oligosaccharides in the extract stock at 80 to 90 ° C., and then mixing honey with fructose and caramel. The mixed solution is sterilized at 90 to 100 ° C. for 15 to 30 seconds to improve degenerative arthritis. Obtaining a natural beverage.
이때, 상기한 본 발명에서 얻어진 퇴행성관절염개선 천연 음료를 캔 또는 그와 유사한 소정용기에 충진하여 120 내지 125℃에서 15 내지 18분간 고압 살균하는 단계를 포함할 수 있다.At this time, the degenerative arthritis improved natural beverage obtained in the present invention may include the step of autoclaving for 15 to 18 minutes at 120 to 125 ℃ by filling in a can or a similar container.
본 발명의 음료 조성물에 함유되는 유효성분의 효능은 다음과 같다.The efficacy of the active ingredient contained in the beverage composition of the present invention is as follows.
글루코사민Glucosamine
포도당에 클루타민이라는 아미노산으로 구성된 물질로 연골, 피부, 손톱, 머리카락을 비롯한 신체 조직구조를 이루는 중요한 성분이다.It is a substance composed of amino acid called glutamine in glucose and is an important component of body tissue including cartilage, skin, nail and hair.
천연 아미노당의 일종인 글루코사민은 염의 형태로 유럽 등에서 변형성관절염의 치료약으로 사용되고 있으며, 또한, 미국에서는 5∼6년 전부터 영양 보조식품으로 판매되어 큰 시장을 형성하고 있다. 또한, 일본에서는 이미 오래전부터 식품 첨가물로 등재되어 사용되고 있으며, 관절을 혹사하는 운동선수, 노인, 노약자, 관절염을 앓고 있는 환자 등에 여러 식품 소재로써 일본 건강??영양식품협회에 의하여 규격기준을 가성하는 실정이다. 글루코사민은 당단백질, 당지질 및 뮤코다당체등의 중요한 생체성분으로서 널리 분포되어 있는 대표적인 천연아미노당이다.Glucosamine, a type of natural amino sugar, is used in Europe as a salt for treating osteoarthritis. In the United States, Glucosamine has been marketed as a nutritional supplement for five to six years. In addition, it has been listed as a food additive in Japan for a long time, and has been approved by the Japan Health & Nutrition Association as a food ingredient for athletes, elderly people, the elderly, and patients suffering from arthritis. It is true. Glucosamine is a representative natural amino sugar widely distributed as important biological components such as glycoproteins, glycolipids, and mucopolysaccharides.
글루코사민은 생체중의 여러 가지 복합 당질의 당쇄중에 구성단위로 존재한다. 그 대표적인 것이 콘드로이친황산이나 히아론산의 뮤코다당류를 포함하는 프로테오글리칸이며, 종합조직, 피부조직, 연골 및 관절액등에 많이 분포되어 있다. 이들은 높은 보습효과를 가지고 세포의 기능이나 형태를 유지하며 윤활작용, 세포접착, 증식, 분화 등의 세포표면에 있어서 중요한 기능을 담당하고 있다.Glucosamine exists as a structural unit in the sugar chains of various complex saccharides in vivo. The most representative of these is proteoglycans containing mucopolysaccharides of chondroitin sulfate and hyaluronic acid, and are widely distributed in comprehensive tissues, skin tissues, cartilage and joint fluids. They have high moisturizing effect, maintain cell function and shape, and play important functions in cell surface such as lubrication, cell adhesion, proliferation and differentiation.
글루코사민은 모유중의 올리고당이 구성단위이며, 비피더스균의 증식인자로 작용한다. 각종 장내세균에 의한 기질 이용성을 글루코스, 락토오스와 비교하여 나타내었는데(표 1), 글루코사민은 장내 세균에 의한 기질로서 이용되기가 어려우므로 소화액의 분비로 pH의 저하 때문에 장내에서 유익한 균인 비피더스균의 증식을 돕고 반대로 유해한 균의 증식을 억제하므로 장내 미생물의 균총을 변화시켜 영양분의 흡수를 돕고 유해성분의 체내 배출 및 적당한 수분의 유지로 정상적인 변으로 변화시켜주므로 변비 개선효과 등 많은 유익효과를 부여한다.Glucosamine is composed of oligosaccharides in breast milk and acts as a growth factor for bifidus bacteria. The use of substrates by various intestinal bacteria was compared with glucose and lactose (Table 1). Since glucosamine is difficult to be used as a substrate by intestinal bacteria, the growth of bifidobacteria, a beneficial bacterium in the intestine, is due to the decrease in pH due to the secretion of digestive fluids. In contrast, by inhibiting the growth of harmful bacteria, by changing the flora of the intestinal microflora, it aids the absorption of nutrients and changes the normal stool by releasing harmful substances in the body and maintaining proper moisture, thereby giving many beneficial effects such as constipation improvement.
또한, 글루코사민염의 변형성관절염(퇴행성관절염)에 대한 치료효과에 대하여 많은 연구가 진행되었다. 변형성관절염 환자 30명을 2군으로 나누고 시험군에는 글루코사민황산염을 400mg/l 일씩 7일간 주사에 의해 투여하고 그 후 2 주간 1.5g/l일씩 경구 투여하였다(대조군은 과절염 치료제를 동량 사용하였다). 그 결과, 주사투여기간중에는 대조군과 함께 개선되었지만, 시험군에서 특히 관절의 회복이 현저하였다. 기능투여 기간에도 시험군이 증상의 개선이 현저하였으나, 대조군은 치료전의 상태로 되돌아갔다. 개선되었지만, 시험군에서 특히 관절의 회복이 현저하였다. 기능 투여기간에도 시험군이 증상의 개선이 현저하였으나, 대조군은 치료전의 상태로 되돌아갔다. 글루코사민의 투여는 부작용이 없는 변형성관절염의 치료제로서 적합하였다.In addition, many studies have been conducted on the therapeutic effect of glucosamine salts for degenerative arthritis (degenerative arthritis). Thirty patients with osteoarthritis were divided into two groups, and the test group was administered glucosamine sulfate by injection for 7 days at 400 mg / l for 7 days, and then orally at 1.5 g / l for 2 weeks (the control group used the same amount of anti-arthritis treatment). . As a result, it improved with the control group during the injection period, but the recovery of the joint was remarkable especially in the test group. In the administration period, the test group showed significant improvement of symptoms, but the control group returned to the state before treatment. Although improved, the recovery of joints was particularly pronounced in the test group. In the period of functional administration, the test group showed significant improvement of symptoms, but the control group returned to the state before treatment. Administration of glucosamine was suitable as a therapeutic agent for osteoarthritis with no side effects.
메틸 술포닐 메탄(MSM)Methyl Sulfonyl Methane (MSM)
MSM을 이해하기 위해서는 생물학적 유황의 인체에 미치는 기능에 대하여 이해하여야 한다. 생물학적 유황은 인체에 있어서 매우 중요한 미네랄이다. 이것은 황함유 아미노산(메티오닌, 시스테인, 시스틴)의 구성물질이며, 타우린, 글루타치온 등의 화학구조의 일부를 이루는 산-형성 아미노산이다. 생물학적 유황이 우리인체에서의 중요한 기능은 항균작용, 비만 및 알레르기의 해독제로 널리 사용되며, 산화작용을 돕고 심장운동을 정상화시키고, 순환을 향상시키며, 혈액에서의 유산소 매체로서 작용한다. 또한, 신체 노화작용을 느리게 하고 삶을 연장시킨다. 이런 생물학적 유황의 부족은 심리적인 스트레스, 육체적 피로감의 축적 그리고 기관과 세포의 악기능 뿐만 아니라 피곤과 질병에 대한 저항성이 떨어진다. 더욱이, 손톱이나 머리카락의 성장부족과 더불어 피부염이나 비만, 알레르기, 변비 등의 신체적인 불균형 상태를 유발시킨다.To understand MSM, it is necessary to understand the function of biological sulfur on the human body. Biological sulfur is a very important mineral for the human body. It is a constituent of sulfur-containing amino acids (methionine, cysteine, cystine) and is an acid-forming amino acid that forms part of the chemical structure of taurine, glutathione and the like. Biological sulfur is widely used as an antidote for antibacterial activity, obesity and allergy in human body, and it helps to oxidize, normalize cardiovascular exercise, improve circulation, and act as aerobic medium in blood. It also slows body aging and prolongs life. This lack of biological sulfur is less resistant to fatigue and disease, as well as psychological stress, accumulation of physical fatigue and bad function of organs and cells. In addition, lack of growth of nails and hair, as well as physical imbalances such as dermatitis, obesity, allergies, constipation.
MSM은 모든 형태의 관절염, 근유경련, 감염성 기생충을 포함하는 스트레스나 속쓰림, 알레르기 반응, 약물 과민성, 점막의 염증, 순환계질환, 염증질환 등을 포함한 심리적인 증상을 정상화시키는데 도움을 준다. 뿐만 아니라, 비타민 C의 전구체이며 근육조직의 효과적인 에너지원 보조제로서 사용되기도 한다.MSM helps to normalize psychological symptoms including all forms of arthritis, muscle spasms, infectious parasites, including stress or heartburn, allergic reactions, drug hypersensitivity, mucosal inflammation, circulatory diseases, and inflammatory diseases. In addition, it is a precursor of vitamin C and used as an effective energy source supplement for muscle tissue.
MSM의 다른 효과를 언급하지 않더라도 이러한 것만으로도 사람의 에너지 수준은 증가되고 오랫동안 유지될 수 있다. 또한, 적당한 양의 MSM은 세포근육조직내에서 젖산 생성을 소멸시켜주는 것을 도와주며, 세포벽의 유연성을 회복시키는데 도움을 준다.Even without mentioning other effects of MSM, this alone can increase human energy levels and sustain them for a long time. In addition, the appropriate amount of MSM helps to eliminate lactic acid production in cell muscle tissue and to restore cell wall flexibility.
키토산올리고당Chitosan oligosaccharide
키틴, 키토산은 천연 다당류로서 최근에 그 생리적 기능이 우수하여 주목받고 있는 기능성 소재이다. 키틴은 게, 새우 등의 갑각류 껍질 부분에 함유되어 있으며 보통 용매에 불용성이므로 그 용도가 매우 한정되어 대부분 키토산의 원료로 사용되고 있으며, 키토산은 키틴을 강알카리로 탈아세틸화하여 제조하고 있다.Chitin and chitosan are natural polysaccharides, which are recently attracting attention due to their excellent physiological functions. Chitin is contained in crustacean shells such as crabs and shrimps, and is generally insoluble in solvents, so its use is very limited, and it is mostly used as a raw material for chitosan. Chitosan is prepared by deacetylating chitin with strong alkali.
최근, 키틴, 키토산 및 그 올리고당의 유도체가 면역증강 및 항암작용, 콜레스테롤 개선 및 고혈압 억제작용 등의 여러 가지 우수한 생리활성을 가지고 있음이 밝혀짐으로써 생리기능성 신소재로 개발되고 있다. 이러한 키토산은 분자량이 매우 크고 용해도가 낮아 우수한 생리활성을 가지고 있음에도 불구하고 그 응용의 폭이 제한되고 있으나, 키토산올리고당은 이러한 문제점을 해결하여 키토산의 생리활성을 가지면서 체내 흡수율을 증가시켰다.Recently, chitin, chitosan and its oligosaccharide derivatives have been developed as a new physiologically functional material, as it has been found to have various excellent physiological activities such as immune enhancement and anticancer activity, cholesterol improvement and hypertension suppression. Although chitosan has a very high molecular weight and low solubility and has excellent physiological activity, its application is limited, but chitosan oligosaccharides have solved this problem and have increased physiological activity of chitosan while increasing the absorption in the body.
본 발명의 음료 조성물에 함유되는 키토산올리고당은 면역력 증가작용, 혈당상승억제작용, 콜레스테롤 조정작용, 발암물질 및 방사능물질의 체내 배출작용, 유해중금속 체내 배출작용, 및 체내 유익균의 증식작용을 나타낸다.Chitosan oligosaccharides contained in the beverage composition of the present invention exhibits an increase in immunity, an effect on suppressing blood sugar elevation, cholesterol regulation, release of carcinogens and radioactive substances, release of harmful heavy metals, and proliferation of beneficial bacteria in the body.
또한, 본 발명의 음료 조성물에 함유되는 한약재 추출물은 한약재를 청수에 가하고 97℃에서 8시간 동안 가열한 후에, 여과함으로써 얻을 수 있으며, 한약재 각각의 효능은 다음과 같다.In addition, the herbal extract contained in the beverage composition of the present invention can be obtained by adding the herbal medicine to fresh water and heated at 97 ° C. for 8 hours, followed by filtration, and the efficacy of each herbal medicine is as follows.
녹용은 간 기능 강화 및 신경 안정작용, 성기능 강화, 피로회복, 강장·강정작용, 근육과 뼈의 강화, 및 중추신경 흥분작용을 나타낸다.Deer antler has liver function enhancement and nerve stabilization, sexual function enhancement, fatigue recovery, tonic and gangjeong action, muscle and bone strengthening, and central nervous excitability.
복분자는 간을 보하고, 축소변, 조음, 이뇨작용 및 여성호르몬과 유사한 작용을 한다.Bokbunja, the liver, contracting stool, articulation, diuretic and female hormones have a similar effect.
맥문동은 아스파라긴, 콜린, 알기닌, 여러 가지 스테로이드 사포닌, 비타민 등을 함유하여 강장, 피로회복, 식용증진, 정신안정에 효과가 있다.Macmundong contains asparagine, choline, arginine, various steroids saponins, vitamins, etc. It is effective in tonic, fatigue, food intake and mental stability.
가시오가피는 인체에 유해한 자극 완화 및 근육강화의 효능이 있으며, 뼈 조직 보한다.Prickly tortoise has the effects of stimulating the stimulation and strengthening the muscles, which are harmful to the human body.
구기자는 신경쇠약 및 신경안정작용이 있으며, 비타민류가 풍부하여 질병에 대한 저항력을 증강시켜 주며 노화를 예방한다.Goji has a nervous breakdown and nerve stabilizing effect, rich in vitamins to increase resistance to disease and prevent aging.
백출은 강장·강정(정력)의 효과가 크며, 위액분비를 촉진하여 위를 다스리는 건위약으로 사용된다.Baekchul has the effect of tonic and gangjeong (energetic), and promotes the secretion of gastric juice, it is used as a gastric placebo to rule the stomach.
두충은 복은 중층의 강압작용이 현저히 크며, 항균작용, 항염증, 진통작용 및 혈압강화작용이 있다.The worms have a significant suppression of the middle layer of the stomach, antibacterial, anti-inflammatory, analgesic and blood pressure strengthening action.
당귀는 피로회복, 식용증진, 강정에 효과가 탁월하며, 관상동맥의 혈류량을 증가시켜 피투이트린(Pituitrin)에 의하여 생기는 심근허혈을 예방하는데 효과가 크다.Angelica excels in fatigue recovery, food intake, and strengthening, and increases the blood flow in the coronary arteries and is effective in preventing myocardial ischemia caused by Pituitrin.
갈근은 뇌혈관과 관상동맥을 확장시킬 수 있어 뇌하수체 후엽 호르몬에 의해 발생하는 급성심근허혈을 예방할 수 있다.Brown roots can dilate cerebrovascular and coronary arteries to prevent acute myocardial ischemia caused by the pituitary gland hormone.
모과는 관절염에 붓기가 빠지는 작용과 넓적다리 근육의 경련, 관절종통 등에 사용된다.Chinese quintes are used to reduce swelling in arthritis, cramps in the thigh muscles, and joint pain.
본 발명의 퇴행성관절염 개선 음용 조성물은 하루에 100 내지 160ml(g)의 양으로 음용할 수 있으며, 바람직하게는 식전 1시간 내지 1시간 30분과 취침 1시간 내지 1시간 30분전 일일 2회씩 매회 50 내지 80ml(g)의 양으로 복용할 수 있다.Degenerative arthritis improved drinking composition of the present invention may be drinkable in an amount of 100 to 160ml (g) per day, preferably 50 to 2 times each day 1 hour to 1 hour 30 minutes before meals and 1 hour to 1 hour 30 minutes before bedtime Can be taken in an amount of 80 ml (g).
본 발명의 음료 조성물은 40대 이후에 점진적으로 진행되어 50대에 이르러 호발하는 신경통, 특히, 관절을 구성하는 연골과 그 주위의 뼈에 퇴행성 변화가 나타나서 생기는 관절염으로 오랫동안 방치하면 관절의 변형까지 초래하는 퇴행성관절염 등 신체적 노화에 따른 질병을 개선하는 효과가 있다.The beverage composition of the present invention gradually progresses after the 40's and reaches the 50's, causing neuralgia, especially arthritis caused by degenerative changes in the cartilage constituting the joint and the bones around it, resulting in deformation of the joint. It is effective to improve diseases caused by physical aging, such as degenerative arthritis.
실시예 1Example 1
천연 한약재를 엄격히 선별하여 청수를 가한 후 97℃에서 8시간 동안 추출하여 여과한 후 추출원액을 얻었다. 추출원액에 글루코사민, MSM, 키토산올리고당을 85℃에서 혼합한 후 꿀과 과당, 그리고 카라멜을 혼합하여 균질화한 후 혼합액을 95℃로 보정된 HTST(고온 살균기)에서 15초 고온 살균처리하여 퇴행성관절염 개선 천연 음료 조성물을 제조하였다.Natural herbal medicines were strictly selected, fresh water was added, extracted at 97 ° C. for 8 hours, filtered, and the crude stock was extracted. Glucosamine, MSM, and chitosan oligosaccharides were mixed at 85 ° C, homogenized by mixing honey, fructose and caramel, and the mixed solution was sterilized for 15 seconds in a high temperature sterilizer (HTST) calibrated at 95 ° C to improve degenerative arthritis. A natural beverage composition was prepared.
상기된 바와 같은 방법으로 퇴행성관절염 개선 음료 조성물을 제조하는데 사용되는 각각의 성분 및 그 함량은 다음과 같다.Each of the components and their contents used to prepare the degenerative arthritis improving beverage composition by the method as described above are as follows.
녹용 추출액(유효성분, 유기물 및 무기물, 즉, 고형분 3) : 1.50중량Deer antler extract (active ingredient, organic substance and inorganic substance, ie solid content 3): 1.50 weight
가시오가피 추출액(고형분 3): 10중량Prickly Pear Extract (Solid 3): 10 wt.
복분자 추출액(고형분 3): 7중량Bokbunja extract (solid content 3): 7 weight
맥문동 추출액(고형분 3): 12중량Macmundong Extract (Solid 3): 12
구기자 추출액(고형분 3): 8중량Wolfberry extract (solid 3): 8 weights
법제두충 추출액(고형분 3): 12중량Legal Tofu Extract (Solid 3): 12 Weight
백출 추출액(고형분 3): 7중량White extraction extract (solid content 3): 7 weight
당귀 추출액(고형분 3): 12중량Angelica extract (solid 3): 12 weights
모과 추출액(고형분 3): 12중량Chinese quince extract (solid content 3): 12 weight
갈근 추출액(고형분 3): 12중량Brown root extract (solid content 3): 12 weight
글루코사민: 0.6중량Glucosamine: 0.6 weight
MSM: 0.6중량MSM: 0.6 Weight
키토산올리고당: 0.1중량Chitosan oligosaccharides: 0.1 weight
꿀: 2.5 중량Honey: 2.5 weight
액상과당: 2.5중량Liquid fructose: 2.5 weight
카라멜: 0.2중량Caramel: 0.2 weight
상기 제조된 퇴행성관절염 개선 천연 음료 조성물을 50대 성인 남, 여 각각 10명을 1개조로 하여 60명을 대상으로 퇴행성관절염의 일반적인 증상을 항목으로 하여 퇴행성관절염 개선 실험을 실시하였다. 음용 방법은 아침에 식전 1시간과 취침 1시간전 일일 2회씩 15일간 음용하도록 한 후에 퇴행성관절염 개선 효과에 대한 관능 검사를 실시하였다.The degenerative arthritis-improved natural beverage composition of the 50 adult male, 10 women each with a set of 60 patients with degenerative arthritis was conducted to improve the symptoms of degenerative arthritis. Drinking method was to drink twice a day for 1 hour before meals and 1 hour before bed in the morning for 15 days, and then sensory tests were performed to improve the degenerative arthritis.
검사시의 점수는 다음과 같이 부여하였다.The score at the time of examination was given as follows.
1...... 전혀 효과가 없다.1 ...... No effect at all.
2...... 별로 효과가 없다.2 ...... Not very effective.
3...... 보통이다.3 ...... Normal.
4...... 조금 효과가 있다.4 ...... a little effective.
5...... 아주 효과가 있다.5 ...... Very effective.
참조예 1Reference Example 1
실시예 1에서 얻은 추출원액을 87℃로 유지된 혼합기로 이송한 후 다음의 조성비에 따라 기능성 소재의 양을 반으로 줄여 동일한 제조방법으로 퇴행성관절염 개선 천연 음료 조성물을 제조하였다.The extract stock solution obtained in Example 1 was transferred to a mixer maintained at 87 ° C., and then the amount of functional material was reduced in half according to the following composition ratio to prepare a degenerative arthritis-improving natural beverage composition by the same manufacturing method.
녹용 추출액(고형분 3) : 1.50중량Deer Antler Extract (Solid 3): 1.50 weight
가시오가피 추출액(고형분 3): 10중량Prickly Pear Extract (Solid 3): 10 wt.
복분자 추출액(고형분 3): 7중량Bokbunja extract (solid content 3): 7 weight
맥문동 추출액(고형분 3): 12중량Macmundong Extract (Solid 3): 12
구기자 추출액(고형분 3): 8중량Wolfberry extract (solid 3): 8 weights
법제두충 추출액(고형분 3): 12중량Legal Tofu Extract (Solid 3): 12 Weight
백출 추출액(고형분 3): 7중량White extraction extract (solid content 3): 7 weight
당귀 추출액(고형분 3): 12중량Angelica extract (solid 3): 12 weights
모과 추출액(고형분 3): 12중량Chinese quince extract (solid content 3): 12 weight
갈근 추출액(고형분 3): 12중량Brown root extract (solid content 3): 12 weight
글루코사민: 0.3중량Glucosamine: 0.3 weight
MSM: 0.3중량MSM: 0.3 weight
키토산올리고당: 0.05중량Chitosan oligosaccharide: 0.05 weight
꿀: 2.8중량Honey: 2.8 weight
액상과당: 2.8중량Liquid fructose: 2.8 weight
카라멜: 0.25중량Caramel: 0.25 weight
상기 제조된 참조 목적의 퇴행성관절염 개선 천연 음료 조성물을 실시예 1에서와 동일한 방법으로 퇴행성관절염 개선 효과에 대한 관능 검사를 실시하였다.The degenerative arthritis-improving natural beverage composition prepared for reference purposes was subjected to a sensory test for the degenerative arthritis-improving effect in the same manner as in Example 1.
참조예 2Reference Example 2
실시예 1의 천연 약재의 배합 비율을 달리한 후 제조방법은 동일하게 하여 퇴행성관절염 개선 천연 음료 조성물을 제조하였다.After changing the blending ratio of the natural medicine of Example 1 was prepared in the same manner to prepare a degenerative arthritis improved natural beverage composition.
녹용 추출액(고형분 3) : 1.50중량Deer Antler Extract (Solid 3): 1.50 weight
가시오가피 추출액(고형분 3): 10중량Prickly Pear Extract (Solid 3): 10 wt.
복분자 추출액(고형분 3): 12중량Bokbunja extract (solid content 3): 12 weight
맥문동 추출액(고형분 3): 7중량Macmundong Extract (Solid 3): 7 weight
구기자 추출액(고형분 3): 12중량Wolfberry Extract (Solid 3): 12
법제두충 추출액(고형분 3): 8중량Legal Tofu Extract (Solid 3): 8 weights
백출 추출액(고형분 3): 12중량White extract (solid 3): 12 weights
당귀 추출액(고형분 3): 7중량Angelica extract (solid content 3): 7 weight
모과 추출액(고형분 3): 8중량Chinese quince extract (solid content 3): 8 weight
갈근 추출액(고형분 3): 16중량Brown root extract (solid 3): 16 weights
글루코사민: 0.6중량Glucosamine: 0.6 weight
MSM: 0.6중량MSM: 0.6 Weight
키토산올리고당: 0.1중량Chitosan oligosaccharides: 0.1 weight
꿀: 2.5중량Honey: 2.5 weight
액상과당: 2.5중량Liquid fructose: 2.5 weight
카라멜: 0.2중량Caramel: 0.2 weight
상기 제조된 참조 목적의 퇴행성관절염 개선 천연 음료 조성물을 실시예 1에서와 동일한 방법으로 퇴행성관절염 개선 효과에 대한 관능 검사를 실시하였다.The degenerative arthritis-improving natural beverage composition prepared for reference purposes was subjected to a sensory test for the degenerative arthritis-improving effect in the same manner as in Example 1.
참조예 3Reference Example 3
효능성분을 첨가하지 않음을 제외하고는 실시예 1에서와 유사한 방법으로 천연음료를 제조하였다.A natural beverage was prepared in a similar manner as in Example 1 except that no active ingredient was added.
녹용 추출액(고형분 3) : 1.50중량Deer Antler Extract (Solid 3): 1.50 weight
가시오가피 추출액(고형분 3): 10중량Prickly Pear Extract (Solid 3): 10 wt.
복분자 추출액(고형분 3): 7중량Bokbunja extract (solid content 3): 7 weight
맥문동 추출액(고형분 3): 12중량Macmundong Extract (Solid 3): 12
구기자 추출액(고형분 3): 8중량Wolfberry extract (solid 3): 8 weights
법제두충 추출액(고형분 3): 12중량Legal Tofu Extract (Solid 3): 12 Weight
백출 추출액(고형분 3): 7중량White extraction extract (solid content 3): 7 weight
당귀 추출액(고형분 3): 12중량Angelica extract (solid 3): 12 weights
모과 추출액(고형분 3): 12중량Chinese quince extract (solid content 3): 12 weight
갈근 추출액(고형분 3): 12중량Brown root extract (solid content 3): 12 weight
꿀: 3.1중량Honey: 3.1 weight
액상과당: 3.1중량Liquid fructose: 3.1 weight
카라멜: 0.3중량Caramel: 0.3 weight
상기 제조된 음료 조성물을 실시예 1에서와 동일한 방법으로 퇴행성관절염 개선 효과에 대한 관능 검사를 실시하였다.The prepared beverage composition was subjected to the sensory test for the degenerative arthritis improvement effect in the same manner as in Example 1.
비교예Comparative example
현재 시중에서 시판되고 있는 퇴행성관절염 개선 드링크제로서 종래의 음료 조성물(1) 및 음료 조성물(2)을 입수하여 실시예 1에서와 동일한 방법으로 퇴행성관절염 개선 효능을 분석하였다. 상기 종래의 음료 조성물은 각각 LG 생활건강의 "조인트탁터"와 "파나 737카"이다. LG 생활건강의 "조인트닥터"는 인체의 뼈, 연골 등의 조직에 많이 필요한 글루코사민, 콘드로이친, 콜라겐 및 식용 히알루론산을 균형있게 배합하여 약한 연골에 도움이 되는 성분을 공급하는 특수한 영양식품으로 무릎이 불편해 걷기가 힘드신 분, 계단 오르내리기가 힘드신 분 등에게 권장되는 퇴행성관절염 개선 특수 영양식품이다. 또한, 그래미 "파나737카"는 대한민국 특허 제170800호에 기재된 제품으로 본 발명과 유사한 효과를 나타내는 제품이다. 본 제품은 무름, 관절계통등에 효과가 있다고 하는 음료로서 시판되는 제품이다.The conventional beverage composition (1) and beverage composition (2) were obtained as a commercially available degenerative arthritis improvement drink agent, and the efficacy of degenerative arthritis improvement was analyzed in the same manner as in Example 1. The conventional beverage composition is "Joint Tacter" and "Pana 737 Ka" of LG H & H, respectively. "Joint Doctor" of LG H & H is a special nutritious food that provides ingredients that help weak cartilage by combining glucosamine, chondroitin, collagen and edible hyaluronic acid, which are necessary for tissues such as bone and cartilage of the human body. It is recommended for those who have difficulty walking and have difficulty climbing up and down stairs. In addition, Grammy "Pana 737ka" is a product described in the Republic of Korea Patent No. 170800 exhibits a similar effect to the present invention. This product is a commercially available drink that is said to be effective against radish and joint systems.
결과result
상기 실험에 의한 데이터에서 알 수 있는 바와 같이, 본 발명의 음료 조성물은 아주 우수한 퇴행성관절염 개선 효과를 나타내고 있으며, 또한 본 발명의 조성 범위를 벗어난 참조 조성물 및 종래의 음료 조성물에 비해 현저하게 우수한 효과를 나타내고 있음을 알 수 있다.As can be seen from the data of the above experiment, the beverage composition of the present invention shows a very good degenerative arthritis improvement effect, and also has a remarkably superior effect compared to the reference composition and the conventional beverage composition outside the composition range of the present invention. It can be seen that.
본 발명은 신경통, 특히, 관절을 구성하는 연골과 그 주위의 뼈에 퇴행성 변화가 나타나서 생시는 관절염으로 오랫동안 방치하면 관절의 변형까지 초래하는 퇴행성관절염 등의 신체적 노화에 따른 질병을 개선시키는 음료 조성물 및 그 제조방법을 제공한다.The present invention relates to a beverage composition for improving diseases caused by physical aging, such as degenerative arthritis, which leads to deformation of the joint when left for a long time with arthritis caused by neuralgia, in particular, cartilage constituting the joint and the bones around the joint; It provides a manufacturing method.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020000022288A KR100363998B1 (en) | 2000-04-26 | 2000-04-26 | Beverage composition for improving degenerative arthritis and method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020000022288A KR100363998B1 (en) | 2000-04-26 | 2000-04-26 | Beverage composition for improving degenerative arthritis and method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20010097870A true KR20010097870A (en) | 2001-11-08 |
| KR100363998B1 KR100363998B1 (en) | 2002-12-16 |
Family
ID=19667107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020000022288A KR100363998B1 (en) | 2000-04-26 | 2000-04-26 | Beverage composition for improving degenerative arthritis and method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100363998B1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100403182B1 (en) * | 2000-11-27 | 2003-10-30 | 이복임 | The manufacturing process of health drink by using Chim-Mok |
| KR20050049625A (en) * | 2003-11-22 | 2005-05-27 | 심종석 | A healthfull drink effective arthritis |
| KR100775055B1 (en) * | 2006-10-31 | 2007-11-09 | 김도완 | Health functional drink containing collagen from deer extracts and process for preparation thereof |
| JP2008120728A (en) * | 2006-11-13 | 2008-05-29 | Pola Chem Ind Inc | Oral administration composition for arthritis/arthrosis |
| KR102117357B1 (en) * | 2020-02-13 | 2020-06-01 | (주)피엘씨 | Oriental medicine based synthetic nutrition snack composition for dog |
| KR20220111805A (en) * | 2021-02-02 | 2022-08-10 | 이해균 | Compositions containing new methylsulfonylmethane(MSM) with increased arthritis treatment effect and the process of manufacture thereof |
-
2000
- 2000-04-26 KR KR1020000022288A patent/KR100363998B1/en not_active IP Right Cessation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100403182B1 (en) * | 2000-11-27 | 2003-10-30 | 이복임 | The manufacturing process of health drink by using Chim-Mok |
| KR20050049625A (en) * | 2003-11-22 | 2005-05-27 | 심종석 | A healthfull drink effective arthritis |
| KR100775055B1 (en) * | 2006-10-31 | 2007-11-09 | 김도완 | Health functional drink containing collagen from deer extracts and process for preparation thereof |
| JP2008120728A (en) * | 2006-11-13 | 2008-05-29 | Pola Chem Ind Inc | Oral administration composition for arthritis/arthrosis |
| KR102117357B1 (en) * | 2020-02-13 | 2020-06-01 | (주)피엘씨 | Oriental medicine based synthetic nutrition snack composition for dog |
| KR20220111805A (en) * | 2021-02-02 | 2022-08-10 | 이해균 | Compositions containing new methylsulfonylmethane(MSM) with increased arthritis treatment effect and the process of manufacture thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100363998B1 (en) | 2002-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI478709B (en) | A useful oral or enteral composition for the recovery of bodily functions | |
| CN101248873A (en) | Drinking food product with sight protection function | |
| CN111616232A (en) | Children milk powder for promoting bone growth and preparation method thereof | |
| CN109123643A (en) | A kind of preparation method of cereal generation meal ball | |
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| WO2022016774A1 (en) | Composition beneficial for regulating intestinal tract, promoting digestion and improving constipation, and preparation method therefor | |
| CN104643250A (en) | Solid beverage capable of bidirectionally regulating body weight and improving subhealth | |
| CN111616364A (en) | Red ginseng and donkey-hide gelatin beverage and application thereof in health-care beverage | |
| CN111227261A (en) | Prebiotic composition and application thereof | |
| CN106723087A (en) | A kind of tablet containing kelp dietary fiber and preparation method thereof | |
| CN105232907A (en) | Beverage capable of invigorating kidney and strengthening Yang and making method thereof | |
| CN113632851A (en) | Multifunctional children growth milk powder and preparation method thereof | |
| TWI830696B (en) | Compositions for inhibiting muscle fiber degeneration | |
| CN104187643A (en) | All-nutrition formula food for yang-deficiency constitution | |
| KR100363998B1 (en) | Beverage composition for improving degenerative arthritis and method thereof | |
| KR100364000B1 (en) | Sports beverage composition and method thereof | |
| JP2000166467A (en) | Health food containing fermented milk product and herbs | |
| KR100363999B1 (en) | Beverage composition for improving climacteric melancholia and nervous debility and method thereof | |
| DE69823546T3 (en) | PROCESS FOR ACCELERATING THE DIGESTION OF A PROTEIN AND MODIFIED PROTEIN PRODUCT | |
| CN112167639A (en) | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof | |
| CN1943695A (en) | A tortoise preparation and its production technology | |
| CN101129956B (en) | Traditional Chinese medicine for treating rickets | |
| CN110559389A (en) | traditional Chinese medicine wine for treating hyperuricemia, gout and rheumatism and preparation method thereof | |
| CN105249475A (en) | Health care alga agar-agar jelly and preparation method of health care alga agar-agar jelly | |
| CN109700031A (en) | For cleaning intestinal tract, the alimentation composition of enteron aisle toxin expelling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20051128 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |